Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Study Completion Date

September 30, 2007

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

Talabostat mesylate (PT-100) tablets

DRUG

Rituximab

Trial Locations (19)

10016

NYU Medical Center, New York

11040

Long Island Jewish Medical Center, New Hyde Park

11365

Queens Medical Associates, PC, Fresh Meadows

14642

James P. Wilmot Cancer Center/University of Rochester, Rochester

23502

Virginia Oncology Associates-Lake Wright Cancer Center, Norfolk

27157

Wake Forest University Health Sciences, Winston-Salem

27511

Raleigh Hematology/Oncology Clinic, Cary

29672

Cancer Centers of the Carolinas, Seneca

33705

Gulfcoast Oncology Associates, St. Petersburg

34474

Ocala Oncology Center, Ocala

46202

Indiana Oncology/Hematology Consultants, Indianapolis

59101

Hematology/Oncology Centers of the Northern Rockies, Billings

72205

University of Arkansas for Medical Science, Little Rock

73112

Cancer Care Associates/Oklahoma City, Oklahoma City

74136

Cancer Care Associates--Tulsa, Tulsa

77030

MD Anderson Cancer Center, Houston

89135

Nevada Cancer Institute, Las Vegas

02115

Dana Farber Cancer Institute, Boston

79606-5208

Texas Cancer Center/Abilene, Abilene

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Point Therapeutics

INDUSTRY